SUNNYVALE, Calif., June 22, 2011 /PRNewswire/ -- Cepheid (Nasdaq:
CPHD) today announced that Robert
Kwiatkowski, Ph. D., has joined the company as Vice
President of Infectious Disease Research and Development, reporting
to David Persing, M.D., Ph.D.
"Cepheid already offers an impressive menu of eleven highly
regarded Xpert® tests for our GeneXpert® system, but we are working
aggressively to extend our leadership with next-generation
products, including a number that employ extensive multiplexing
capability for panel-based tests, in addition to providing further
test menu consolidation with CT/NG, HIV, HPV and HCV," said Dr.
Persing, Cepheid's Chief Medical and Technology Officer.
"With his wide-ranging experience in the management of
infectious disease test development, Bob is an exciting addition to
a talented scientific team working to develop tests for the most
powerful molecular platform available today."
Dr. Kwiatkowski brings to Cepheid almost two decades of
experience in nucleic acid infectious disease test development and
management, including tests for HPV, HIV and HCV. Prior to
joining Cepheid, Dr. Kwiatkowski was most recently responsible for
managing infectious disease test development in support of multiple
automated platforms at Siemens Healthcare Diagnostics. Dr.
Kwiatkowski has previously held positions at Gentra Systems,
acquired by Qiagen in 2006, Third Wave Technologies, Becton
Dickinson Molecular Diagnostics and Digene Diagnostics. Dr.
Kwiatkowski earned his Ph. D. at the John Hopkins University.
About Cepheid
Based in Sunnyvale, Calif.,
Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company
that is dedicated to improving healthcare by developing,
manufacturing, and marketing accurate yet easy to use molecular
systems and tests. By automating highly complex and time-consuming
manual procedures, the company's solutions deliver a better way for
institutions of any size to access the full power of molecular
diagnostics. The company's systems enable rapid, sophisticated
genetic testing for organisms and genetic-based diseases by
automating otherwise complex manual laboratory procedures. Through
its strong molecular biology capabilities, the company is focusing
on those applications where accurate, rapid, and actionable test
results are needed most, such as managing infectious diseases and
cancer. For more information, visit www.cepheid.com.
This press release contains forward-looking statements that
are not purely historical regarding Cepheid's or its management's
intentions, beliefs, expectations and strategies for the future,
including those relating to product functionality and performance,
future products and future market opportunities. Because such
statements deal with future events, they are subject to various
risks and uncertainties, and actual results could differ materially
from the company's current expectations. Factors that could cause
actual results to differ materially include risks and uncertainties
such as those relating to: unforeseen development and manufacturing
problems; uncertainties in the regulatory review process for new
products; regulatory developments and practices regarding testing;
customer and market acceptance of the product; the failure of the
product to perform as expected, whether due to manufacturing
errors, defects or otherwise; the impact of competitive products
and pricing; potentially lengthy sales cycles in some markets;
reimbursement rates for products; and underlying market conditions
worldwide. Readers should also refer to the section entitled "Risk
Factors" in Cepheid's Annual Report on Form 10-K and in its most
recent quarterly report on Form 10-Q, each filed with the
Securities and Exchange Commission.
All forward-looking statements and reasons why results might
differ included in this release are made as of the date of this
press release, based on information currently available to Cepheid,
and Cepheid assumes no obligation to update any such
forward-looking statement or reasons why results might
differ.
CONTACTS:
|
|
|
For Cepheid Media
Inquiries:
|
For Cepheid Investor
Inquiries:
|
|
Jared Tipton
Cepheid Corporate
Communications
408-400-8377
communications@cepheid.com
|
Jacquie Ross
Cepheid Investor
Relations
408-400-8329
investor.relations@cepheid.com
|
|
|
|
SOURCE Cepheid